LaNova is a biopharmaceutical company focused on the discovery and development of human therapeutics. Its work spans early research, preclinical evaluation, and the chemistry, manufacturing, and controls (CMC) activities needed to progress candidates toward clinical studies.
The company advances a mix of proprietary programs and partnered projects, with capabilities in medicinal chemistry, biologics, and process development. LaNova engages in licensing and technology‑transfer arrangements and supports scale‑up, quality, and regulatory readiness to enable the transition from laboratory to manufacturing.
None yet. When a new project in the record names LaNova as owner, partner or investor, it shows here.
Sales rose 4% to $17.3B. KEYTRUDA up 10%, GARDASIL down 24%. GAAP EPS $2.32, Non-GAAP $2.58. FDA approved KEYTRUDA QLEX. Acquired Verona Pharma. Full-year sales outlook: $64.5B-$65B.
